Considerations for treating acne in ethnic skin

Cutis

Volumn 76, Issue 2 SUPPL., 2005, Pages 19-23

  Callender, Valerie D ^a,b,c,d,e,f  

^a Callender Skin and Laser Center   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c ALLERGAN INC   (United States)

^d Galderma Laboratories   (United States)

^e SkinMedica Inc   (United States)

^f Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; COSMETIC; DICARBOXYLIC ACID; HYDROQUINONE; HYDROQUINONE DERIVATIVE; RETINOID;

ACNE VULGARIS; ARTICLE; DRUG COMBINATION; ETHNOLOGY; FOLLICULITIS; HUMAN; HYPERPIGMENTATION; NEGRO; PATHOPHYSIOLOGY;

ACNE KELOID; ACNE VULGARIS; AFRICAN CONTINENTAL ANCESTRY GROUP; COSMETICS; DICARBOXYLIC ACIDS; DRUG THERAPY, COMBINATION; HAIR PREPARATIONS; HUMANS; HYDROQUINONES; HYPERPIGMENTATION; RETINOIDS;

EID: 24744437142     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17:184-195.
2. Taylor SC, Cook-Bolden F, Rahman Z, et al. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(suppl):S98-S106.
3. Wilkins JW Jr, Voorhees JJ. Prevalence of nodulocystic acne in white and Negro males. Arch Dermatol. 1970;102:631-634.
4. Kelly AP. Keloids: pathogenesis and treatment. Cosmet Dermatol. April 2003;16(suppl 3):29-32.
5. Halder RM, Brooks H, Callender VD. Acne in ethnic skin. Dermatol Clin. 2003;21:609-615.
6. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(suppl 4):48-54.
7. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438-1443.
8. Grimes RB, Callender VD. Tazarotene for postinflammatory hyperpigmentation and acne vulgaris in darker skin. Cutis. In press.
9. Orlow SJ, Chakraborty AK, Pawelek JM. Retinoic acid is a potent inhibitor of inducible pigmentation in murine and hamster melanoma cell lines. J Invest Dermatol. 1990;94:461-464.
10. Yoshimura K, Okazaki M, Virador VM, et al. Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes. J Dermatol Sci. 2001;27(suppl 1):S68-S75.
11. Callender V, Young C. Long-term benefits of adapalene cream maintenance therapy for the treatment of mild to moderate acne and postinflammatory hyperpigmentation [abstract]. J Am Acad Dermatol. 2005;52:P19. Poster P137.
12. Callender VD. An open-label study of the use of adapalene cream and a triple-combination therapy for the treatment of mild-to-moderate acne and post-inflammatory hyperpigmentation [abstract]. J Am Acad Dermatol. 2004;50:P169. Poster P660.
13. Nguyen QH, Bui TP. Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol. 1995;34:75-84.
14. Fitton A, Goa KL. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs. 1991;41:780-798.
15. Grimes PB. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25:18-22.
16. Sachdev MB. Use of superficial glycolic acid chemical peels for varied indications in darker racial ethnic skin types. Poster presented at: American Academy of Dermatology 62nd Annual Meeting; February 6-11, 2004; Washington, DC. P84.
17. Plewig G, Fulton JE, Klingman AM. Pomade acne. Arch Dermatol. 1970;101:580-584.
18. Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg. 2003;29:1050-1051.
19. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. 2002;47(suppl 4):S209-S211.
20. Callender VD. Hyperpigmentation in an African American patient with acne. Cosmet Dermatol. March 2003;16(suppl 2):1-3.
21. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74:362-368.